This CME-accredited expert discussion aims to highlight the unmet needs in late-onset genetic cholestasis and provide guidance on the use of genetic testing in the diagnostic workup and initial management steps for the different genotypes, with reference to key trials and updates from The Liver Meeting 2024: American Association for the Study of Liver Diseases (AASLD).

Register to access

General Information
Title: Unmet needs in late-onset genetic cholestasis: an expert discussion
Jointly provided by Postgraduate Institute for Medicine and Springer Healthcare IME
This program is made possible thanks to an independent educational grant from Ipsen
Release date: December 20th 2024
Expiration date: December 20th 2025
Estimated time to complete activity: 1 hour
Target Audience
This activity is primarily aimed at a global audience of adult hepatologists and gastroenterologists, but is relevant to all members of the multidisciplinary team that manages late-onset genetic cholestatic patients.
Educational Objectives
After completing this activity, the participant should be better able to:
- Recognize the different phenotypes and clinical presentations of late-onset genetic cholestasis
- Integrate consensus recommendations and diagnostic tools to accurately diagnose different types of late-onset genetic cholestasis
- Debate best practice for the current and potential future management of different forms of late-onset genetic cholestasis
Faculty
- Verena Keitel-Anselmino (chair)
Otto von Geuricke University Magdeburg, Germany - Silvia Vilarinho
Yale University, USA - Deepak Joshi
Kings College Hospital NHS Foundation Trust, United Kingdom
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. These relationships have been mitigated:
- Verena Keitel-Anselmino
Honoraria/Consultation fees: Mirum, GSK, Albireo/Ipsen, Falk, AstraZeneca
Stocks, shares or equity: Madrigal
Participation in a company sponsored speaker bureau: Falk, AstraZeneca, Ipsen, Mirum, Albireo, GSK, Gilead, MSD - Silvia Vilarinho
Honoraria/Consultation fees: Alberio, Ipsen, Mirum
Grants/research support: Moderna - Deepak Joshi
Honoraria/Consultation fees: Ipsen Pharma, Mirum, Boston Scientific, Q3 Medical
The PIM planners and others have nothing to disclose. The Springer Healthcare IME planners and others have nothing to disclose.
All relevant financial relationships have been mitigated.
Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Springer Healthcare IME. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Continuing Physician Assistant Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.